{"nctId":"NCT03920215","briefTitle":"Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease","startDateStruct":{"date":"2018-08-15","type":"ACTUAL"},"conditions":["Long Term Follow up Dry Eye Disease"],"count":101,"armGroups":[{"label":"OC-01 Low Dose, 0.12 mg/mL","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: OC-01 Low Dose, 0.12 mg/mL"]},{"label":"OC-01 Mid Dose, 0.6 mg/mL","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: OC-01 Mid Dose, 0.6 mg/mL"]},{"label":"OC-01 High Dose, 1.2 mg/mL","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: OC-01 High Dose, 1.2 mg/mL"]},{"label":"Placebo (vehicle) nasal spray","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (vehicle) nasal spray"]}],"interventions":[{"name":"OC-01 Low Dose, 0.12 mg/mL","otherNames":["OC-01 (varenicline) nasal spray, 0.12 mg/ml"]},{"name":"OC-01 Mid Dose, 0.6 mg/mL","otherNames":[]},{"name":"OC-01 High Dose, 1.2 mg/mL","otherNames":["OC-01 Mid Dose, 1.2 mg/mL"]},{"name":"Placebo (vehicle) nasal spray","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Have been enrolled in the OPP-002 study\n2. Have received at least one dose of the study drug/placebo in OPP-002 study\n3. Completed the OPP-002 study to Visit 5\n4. Have provided verbal and written informed consent\n\nExclusion Criteria:\n\n1\\. Have discontinued prior to Visit 5 in the OPP-002 study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"22 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With the Left Nostril/Abnormal at 6 Months as Assessed by Intranasal Examinations","description":"Number of Participants with the Left Nostril/Abnormal at 6 months as assessed by Intranasal Examinations","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With the Right Nostril/Abnormal at 6 Months as Assessed by Intranasal Examinations","description":"Number of Participants with the Right Nostril/Abnormal at 6 months as assessed by Intranasal Examinations","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With the Left Nostril/Abnormal at 12 Months as Assessed by Intranasal Examinations","description":"Number of Participants with the Left Nostril/Abnormal at 12 months as assessed by Intranasal Examinations","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With the Right Nostril/Abnormal at 12 Months as Assessed by Intranasal Examinations","description":"Number of Participants with the Right Nostril/Abnormal at 12 months as assessed by Intranasal Examinations","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":["Conjunctival oedema","Pain","Nasopharyngitis","Cataract","Conjunctival hyperaemia"]}}}